Examples of using Prograf in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Start prograf.
Prograf cellcept mycophenolate mofetil.
Patients are prescribed either cyclosporin or Prograf.
USA Prograf Order Cheap?
Month graft survival was 85.3% for Advagraf and 85.6% for Prograf.
Prograf astellas hydroxypropyl methylcellulose.
Overdose In cases of accidental Prograf overdose the following symptoms were described.
Prograf and associated names See Annex I.
There are at least sixdirect concertgoers with nicotinic travoprost who received either prograf or sulfasalazine.
Prograf cellcept mycophenolate mofetil Online Apotheke.
Treatment failure occurred in 18.3% patients treated with Envarsus(49 out of 268),and 19.6% given Prograf 54 out of 275.
Prograf astellas hydroxypropyl methylcellulose Online Apotheke.
Failure rates were 2.5% in both groups 4 of 162 patients treated with Envarsus,and 4 of 162 treated with Prograf.
Prograf belongs to the class of medications called immunosuppressants.
The relationship between tacrolimus trough levels(C24) and systemic exposure(AUC 0-24)is similar between the two formulations Advagraf and Prograf.
Prograf capsules or from Advagraf prolonged-release capsules to Envarsus, trough levels should be measured prior to conversion and within two weeks after conversion.
The CHMP gave a positive opinion on 26January 2006 recommending the harmonisation of the SPC for Prograf and associated names.
In stable patients converted from Prograf(twice daily) to Advagraf(once daily) on a 1:1(mg: mg) total daily dose basis the systemic exposure to tacrolimus(AUC0-24) for Advagraf was approximately 10% lower than that for Prograf.
The first study involved 326 patients who hadalready had a kidney transplant and were being treated with Prograf and other immunosuppressants to prevent rejection.
The Agency's Committee for Medicinal Products for Human Use(CHMP) decided that theapproved doses of Envarsus have been shown to have a comparable quality, safety and effectiveness to Advagraf and Prograf.
The treatment difference was -3.0%(Advagraf-ciclosporin)(95.2% confidence interval[-9.9%, 4.0%]) for Advagraf vs. ciclosporin and -1.9%(Prograf-ciclosporin)(95.2% confidence interval[-8.9%,5.2%]) for Prograf vs. ciclosporin.
No studies have been conducted with conversion of patients from Advagraf to Envarsus; however, data from healthy volunteers would suggest thatthe same conversion rate is applicable as with the conversion from Prograf to Envarsus.
Nakanishi and Yamanaka's patentwas for the intravenous injection of the drug Tacrolimus, marketed as Prograf(the drug can also be used in capsule form); they developed the solution at Japan-based Fujisawa Pharmaceutical.
The event rate for centrally-read, biopsy-confirmed acute rejection(BPAR) during the 360-day study was 13.1% in the Envarsus group(N=268)and 13.5% in the Prograf group N=275.
Helping thousands around theworld Nakanishi and Yamanaka's patent was for the intravenous injection of the drug Tacrolimus, marketed as Prograf(the drug can also be used in capsule form); they developed the solution at Japan-based Fujisawa Pharmaceutical.
Dose recommendations- Conversion of Prograf treated patients to Advagraf Allograft transplant patients maintained on twice daily Prograf capsules dosing requiring conversion to once daily Advagraf should be converted on a 1:1(mg: mg) total daily dose basis.
Based on the documentation submitted by the MAH and the scientific discussion within the Committee,the CPMP considered that the benefit/ risk ratio of Prograf and associated names is favourable for use relating to.
Due to the fact that the original product Prograf and associated names does not have the same Summary of Product Characteristics(SPC) in the various Member States in the European Union and due to divergent national decisions, a harmonisation of the SPC for Prograf and associated names, throughout Europe became necessary.
The event rate for locally read biopsy-confirmed acute rejection(BPAR) during the 360 day study was 1.2% in the Envarsus group(N=162) post conversion from Prograf at a dose ratio of 1:0.7(mg:mg) and 1.2% in the group maintained on Prograf N=162.
The CHMP having considered the Rapporteur and the Co-Rapporteur assessment reports, the scientific discussion within the Committee and the comments from the Marketing Authorisation Holders(MAH),was of the opinion that the benefit/ risk ratio of Prograf and associated names is considered to be positive in the following indications.